Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Inclusion Criteria: INDEX CASE * Men and women age greater than or equal to 18 years. * Pulmonary MDR-TB defined as: * Confirmation of rifampin/rifampicin (RIF) resistance and INH resistance by * adequate source documentation (including date of testing, test methodology, and test results) of RIF and INH resistance from a licensed/nationally approved\* referral program, OR * if either or both results are unknown or not adequately documented (as noted above), then confirmation must be obtained using a DAIDS-approved laboratory that operates according to Good Clinical Laboratory Practices (GCLP) guidelines and participates in an appropriate external quality assurance (EQA) program. * \*NOTE: The term "licensed/nationally approved" refers to a laboratory that has been certified or licensed by an oversight body within that country and approved for RIF and/or INH resistance testing. * NOTE: Pre-XDR and XDR TB are not exclusionary. See the A5300B/I2003B/PHOENIx MOPS for study-approved molecular and phenotypic methods. * Started MDR-TB treatment within the past 90 days. * Ability and willingness of the index case to provide informed consent to access the HH and approach HH members for evaluation. * HH of index case has at least one reported HHC. HOUSEHOLD CONTACTS If any member(s) of the HH is/are not eligible or do not want to participate, all other eligible TB contacts within the HH can still participate. * Currently lives or lived in the same dwelling unit or plot …